Loading
Old version — revision 1
This is a fixed snapshot of DNA nanotechnology, saved by Import as part of the initial corpus import. It is not edited and it is not updated; the article may have changed since.
Edit summary: Initial import of content/dna-nanotechnology.md — the filesystem corpus, unchanged. Not an edit.
The use of DNA as a construction material rather than a carrier of genes, folding programmed sequences into nanoscale shapes, devices, and logic-gated containers.
DNA nanotechnology treats DNA as a building material rather than as genetic information. Because base pairing is predictable, a set of synthetic strands can be designed so that the only low-energy configuration they can adopt is a particular shape, and that shape then assembles itself when the strands are mixed and cooled. The field has produced nanoscale objects of arbitrary geometry, molecular machines that walk and compute, and containers that open in response to a chosen biological signal.
The founding insight is that the double helix is not the only structure DNA can form. Branched junctions occur naturally during recombination, but they migrate. Nadrian Seeman proposed in 1982 that by designing sequences with no symmetry, a junction could be made immobile, and immobile junctions could be linked into a rigid lattice.1 That converts DNA from a linear molecule into a construction kit with a programmable connectivity.
DNA origami, introduced by Paul Rothemund in 2006, made the approach practical.2 A single long scaffold strand — usually the genome of the M13 bacteriophage, around 7,200 bases — is folded into a target shape by roughly two hundred short synthetic "staple" strands, each designed to bind two or three distant regions of the scaffold and hold them together. Mixing scaffold and staples and annealing over a few hours yields the designed object in enormous copy number, with folding yields high enough that misassembled structures are usually the minor product; the excess staples are then removed by filtration or gel extraction. Extending the method into three dimensions produced honeycomb and square lattices, then DNA "bricks" that build shapes without a scaffold at all, then assemblies in the gigadalton range.
The resolution is set by the helix: features are addressable at roughly 3 to 6 nanometres, and every position on the structure has a known sequence, so a chemical group, a fluorophore, a protein, or a nanoparticle can be attached at a chosen coordinate. That addressability is the field's real advantage over the self-assembling but unaddressable vesicles of Lipid nanoparticles, and it is what distinguishes it from the mechanical construction proposed in Molecular assembler.
The field moved in two phases. Two decades of structural work established that designed sequences could be made to hold a shape at all, mostly on lattices and polyhedra assembled from strands of similar length. The second phase began when folding a long natural scaffold with cheap synthetic staples turned that into a one-pot procedure any molecular biology laboratory could run, after which the interesting question stopped being whether a shape could be built and became what to attach to it.
Static shapes were the first product; dynamic ones followed. None of them swims: motion in DNA devices means a conformational change or a walker stepping along a track, not locomotion through tissue, which remains the province of the externally steered machines in Medical microrobots. Toehold-mediated strand displacement, in which an incoming strand invades a partially paired duplex from a single-stranded overhang, gives a reliable primitive for state change. Chained together, displacement reactions implement logic gates and multi-layer circuits operating entirely in solution, with no enzymes and no external control. Bipedal DNA walkers move along tracks by the same chemistry.
The medical application of this machinery is conditional release. In 2012 a Harvard group built an origami barrel held shut by two aptamer locks, each of which opens only on binding a specified cell-surface protein; the device carried antibody fragments and released them selectively onto target leukaemia cells in culture.3 The logic was genuinely AND-gated: both antigens had to be present.
The strongest in vivo result to date used a simpler trigger. Origami tubes were loaded with thrombin and closed with an aptamer that binds nucleolin, a protein displayed on tumour endothelium but not on normal vessels. Injected into tumour-bearing mice, the devices opened at the tumour vasculature, released their cargo, and induced local thrombosis, slowing tumour growth in several models.4 It remains the most cited demonstration that a programmable DNA device can produce a therapeutic effect in an animal.
What "nanorobot" means hereThese devices contain no power source, no processor, and no means of locomotion. They circulate passively and change state when a specific molecule binds. Calling them robots is a convention of the field rather than a description of their capabilities, a distinction that matters when comparing them with the designs in Medical nanorobots — Eric Drexler's cell-repair machines and Freitas's respirocyte are specified with onboard sensing, computation, and actuation, none of which an origami device has.
DNA is a poor material for blood. Three problems dominate.
Structures assembled at 10 to 20 millimolar magnesium partially unfold at the roughly 1 millimolar free magnesium of extracellular fluid. Nucleases in serum degrade unprotected origami within hours. And unmethylated CpG motifs in bacterial-derived scaffold sequence are recognised by Toll-like receptor 9, provoking an innate immune response that is useful when the structure is meant to be a vaccine scaffold and unwelcome when it is meant to be a carrier.
Coatings mitigate the first two. Oligolysine conjugated to polyethylene glycol electrostatically wraps the structure, stabilising it at low salt and slowing nuclease attack by an order of magnitude or more.5 Lipid bilayer coatings and protein shells achieve similar effects. None of these has yet carried a DNA device through a human trial, whereas the two crude carriers it competes with — AAV vectors and lipid vesicles — have each delivered approved products.
Payload capacity is a further constraint. An origami barrel holds a handful of protein molecules; a liposome of comparable size holds thousands of small-molecule drugs. For most therapeutic purposes the cargo-to-carrier ratio is unfavourable, which is one reason the clinical successes of nanomedicine have gone to formulations rather than to structures, as described in Targeted drug delivery.
Cost was a fourth constraint until recently. Synthetic staple strands are expensive at scale, and a route that produces both scaffold and staples biologically in bacteriophage-infected bacteria has reduced the price of bulk origami by orders of magnitude, moving gram-scale production from implausible to demonstrated. The same falling cost of writing DNA underpins Synthetic genomes and has made sequence screening at synthesis providers a standing item in Dual-use research of concern policy.
The field's most consistent value has been as a laboratory tool. Origami acts as a molecular breadboard: a rigid, addressable surface for placing molecules at defined distances. DNA-PAINT exploits transient strand binding to achieve super-resolution imaging below the diffraction limit. Origami rulers calibrate microscopes. Nanopore experiments use DNA structures as gates and adapters, connecting to the sensing methods described in Nanoscale diagnostics.
Immunology has produced a distinctive application. Because antigen spacing on a surface strongly affects B-cell activation, origami scaffolds displaying antigens at controlled separations have been used to dissect that dependence and to design immunogens — a use of the technology as a precision instrument rather than as a delivery vehicle.6
DNA is also a storage medium, a line of work associated with George Church among others, and one that shares synthesis and sequencing infrastructure with the fabrication side of the field but little else.
The obstacle to clinical translation is not design but pharmacology: an object made of nucleic acid must survive serum, avoid the liver, escape the endosome, and release cargo where intended, and the field has partial answers to each and a complete answer to none. The most likely first clinical entries are those where DNA's drawbacks matter least — vaccine and immunotherapy scaffolds, where immune recognition is the point, and topical or local applications, where circulation is not involved.
Whether the addressability advantage ever justifies the fragility is the open question. A structure that positions two proteins exactly seven nanometres apart can do things no liposome can. As of 2026 nobody has shown that this buys enough in a patient to outweigh a material that dissolves in blood, and the CRISPR–Cas9 era has meanwhile demonstrated how much can be achieved with delivery vehicles that have no internal architecture at all.
paperSeeman, N.C. "Nucleic acid junctions and lattices." Journal of Theoretical Biology, 1982. ↩
paperRothemund, P.W.K. "Folding DNA to create nanoscale shapes and patterns." Nature, 2006.↩The shapes demonstrated here are two-dimensional; folding into solid three-dimensional objects came from other groups later.
paperDouglas, S.M., Bachelet, I., Church, G.M. "A logic-gated nanorobot for targeted transport of molecular payloads." Science, 2012.↩The AND-gated release was demonstrated on cultured cells in a dish; the mouse work that followed used a simpler single-aptamer trigger.
paperLi, S. et al. "A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo." Nature Biotechnology, 2018.↩The therapeutic effect is in tumour-bearing mice; nothing comparable has been reported in people.
paperPonnuswamy, N. et al. "Oligolysine-based coating protects DNA nanostructures from low-salt denaturation and nuclease degradation." Nature Communications, 2017. ↩
paperVeneziano, R. et al. "Role of nanoscale antigen organization on B-cell activation probed using DNA origami." Nature Nanotechnology, 2020. ↩